Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Drug screening in Drosophila for repurposing in neuropsychiatry

ABSTRACT: Drug screening in Drosophila for repurposing in neuropsychiatry

PROVIDER: PRJNA596785 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Drug repurposing via ultra-high throughput 3D spheroids screening in rare cancer treatment

Project description:Rare cancers comprise over 200 distinct types accounting for 20–25% of U.S. cancer diagnoses yet receive limited therapeutic investment due to small patient populations and resource constraints. Drug repurposing offers a viable strategy, and large-animal models such as minipigs provide physiologically realistic platforms for preclinical evaluation. However, scalable systems for systematically screening large drug libraries in rare cancer models remain unavailable. We developed an integrated pipeline combining a minipig spinal cord glioma (SCG) model with miniaturized ultra-high-throughput screening (uHTS). Primary SCG cells were cultured in 3D platforms for rapid screening of bioactive compounds. Lead candidates underwent validation through 3D spheroid assays, in vivo xenografting, RNA sequencing, immunohistochemistry, and histological analysis. Human SCG tissue samples and population-level datasets assessed translational relevance. uHTS screening identified Clofoctol as a lead compound with potent glioma growth inhibition in both primary SCG cells and xenograft models. Mechanistic studies revealed pleiotrophin (PTN) as a key target, with confirmatory expression patterns in human SCG samples, establishing translational validity. Integration of large-animal cancer models with drug-repurposing pipelines and uHTS platforms is feasible and effective for rare cancer drug discovery. This approach successfully identified Clofoctol, an FDA-approved compound with therapeutic potential for spinal cord gliomas and establishes a scalable model applicable to other orphan cancers.

2026-06-20 | GSE335535 | GEO

Transcriptomics-based Screening of Repurposing Drug for Idiopathic Pulmonary Fibrosis

Project description:Transcriptomics-based Screening of Repurposing Drug for Idiopathic Pulmonary Fibrosis

| PRJNA1232167 | ENA

Drug screening in Drosophila for repurposing in neuropsychiatry

Project description:The study analyses the effect of multiple drugs on transcriptomic profile of Drosophila melanogaster. At the end of treatment, the head tissues were collected and homogenized in trizol for RNA extraction. The transcriptomic profiling was done using Affymetrix Drosophila Genome 2.0 array.

2022-12-01 | GSE142384 | GEO

Drug repurposing via ultra-high throughput 3D spheroids screening in rare cancer treatment

Project description:Drug repurposing via ultra-high throughput 3D spheroids screening in rare cancer treatment

| PRJNA1478839 | ENA

Drug repurposing in rare diseases: an integrative study of drug screening and transcriptomic analysis in nephropathic cystinosis

Project description:Drug repurposing in rare diseases: an integrative study of drug screening and transcriptomic analysis in nephropathic cystinosis

| PRJNA766553 | ENA

Transcriptomics-based Screening of Repurposing Drug for Idiopathic Pulmonary Fibrosis

Project description:IPF is a pathological condition resulting from injury to the lungs and an ensuing fibrotic response leading to thickening of the alveolar walls and the obliteration of the alveolar space. The etiology of IPF and the role of the microenvironment in disease progression are largely unknown. We first used the repurposing pipeline to explore disease biology for the identification of relevant cell populations and then applied the screening pipeline to discover novel compounds. Using various types of RNAseq data from multiple datasets, we constructed signatures that capture different aspects of IPF biology, such as those related to cell type-specific transcriptional changes and those associated with disease development in animal models. We predicted and tested drugs targeting various IPF signatures and identified Pyrithyldione as our top candidate for reduction of fibrosis in the human precision-cut lung slices PCLS model and RNAseq was conducted on treated and untreated paired adjacent patient samples to determine its the effects on gene expression.

2025-12-16 | GSE291190 | GEO

20230905 ReFRAME drug repurposing collection DDA spectra

Project description:DDA analysis of 14,000 drugs in the ReFRAME drug repurposing collection. Positive and negative ionizations.

| MSV000092822 | MassIVE

Machine Learning Identifies Candidates for Drug Repurposing in Alzheimer's Disease

Project description:Clinical trials of novel therapeutics for Alzheimer's Disease (AD) have consumed a large amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA) for another indication is a more rapid and less expensive option. In this study, we profile 80 FDA-approved and clinically tested drugs in neural cell cultures, with the goal of producing a ranked list of possible repurposing candidates.

2021-01-14 | GSE164788 | GEO

Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis [Tissue_RNA-seq]

Project description:we present a novel path to drug repurposing to identify new immunotherapies for ASCVD. The integration of time of-flight mass cytometry (CyTOF) and RNA-sequencing identified unique inflammatory signatures in peripheral blood mononuclear cells (PBMCs) stimulated with ASCVD plasma. By comparing these inflammatory signatures to large-scale gene expression data from the LINCS L1000 dataset, we identified drugs that could reverse this inflammatory response. In conclusion, a systems immunology-driven drug repurposing with pre- clinical validation strategy can aid the development of new cardiovascular immunotherapies.

2023-04-23 | GSE230216 | GEO

Systems immunology-based drug repurposing framework to target inflammation in atherosclerosis [DRUG_RNA-seq]

2023-04-23 | GSE230215 | GEO